Alteplase for ischemic stroke: A giant with feet of clay?
- 3 August 2022
- journal article
- editorial
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 146 (3), 318-319
- https://doi.org/10.1111/ane.13661
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationStroke, 2019
- Intravenous Recombinant Tissue Plasminogen Activator and Ischemic Stroke: Focused Update of 2010 Clinical Practice Advisory From the American Academy of Emergency MedicineThe Journal of Emergency Medicine, 2018
- Review article: Why is there still a debate regarding the safety and efficacy of intravenous thrombolysis in the management of presumed acute ischaemic stroke? A systematic review and meta‐analysisEmergency Medicine Australasia, 2016
- The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility IndexJournal of Clinical Epidemiology, 2014
- Details of a Prospective Protocol for a Collaborative Meta-Analysis of Individual Participant Data from all Randomized Trials of Intravenous rt-PA vs. Control: Statistical Analysis Plan for the Stroke Thrombolysis Trialists' Collaborative Meta-AnalysisInternational Journal of Stroke, 2013
- A Graphic Reanalysis of the NINDS TrialAnnals of Emergency Medicine, 2009
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeThe New England Journal of Medicine, 2008
- Thrombolysis for stroke: Policy should be based on science, and not on politics, money or fear of malpracticeEmergency Medicine Australasia, 2006
- Truths about the NINDS study: setting the record straightWestern Journal of Medicine, 2002
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995